Q&A: What the Executive Order on Regulations Could Mean for EPA, FDA

A conversation with public health expert Lynn Goldman, a former assistant administrator at the US Environmental Protection Agency

Written byJoshua A. Krisch
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The headquarters of the United States Environmental Protection Agency in Washington, D.CWIKIMEDIA, COOLCAESERPresident Donald Trump signed an executive order on January 30, requiring that federal agencies repeal two regulations for every new one they propose. In a statement, Rick Pollack, chief executive officer of the American Hospital Association, praised the order as a step toward removing “red tape” that can drive up health care costs. Meanwhile, Joan Claybrook, former head of the National Highway Traffic Safety Administration, had a decidedly less optimistic reaction. “People are going to die if you start eliminating safety standards,” she told the Los Angeles Times.

Lynn Goldman, dean of the George Washington University Milken Institute School of Public Health and a former assistant administrator for the Environmental Protection Agency (EPA)’s Office of Chemical Safety and Pollution Prevention, spoke with The Scientist about the executive order, and the impact it may have on federal agencies including the EPA and the Food and Drug Administration (FDA).

The Scientist: What do you think was President Trump’s goal in issuing this order?

Lynn Goldman: I think his intent is to follow through on a commitment made in the campaign to reduce regulation, and I believe there was then a verbal commitment that, for every regulation issued, two would be eliminated. And, overall, there are many supporters of the president who sense the importance of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies